<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01028859</url>
  </required_header>
  <id_info>
    <org_study_id>127ASC09E</org_study_id>
    <nct_id>NCT01028859</nct_id>
  </id_info>
  <brief_title>Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers</brief_title>
  <official_title>Phase I Clinical Trial to Assess the Safety and Pharmacokinetic Profile of CKD-516 in Patients With Advanced Solid Cancers Failed to Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I study is conducted to determine the maximum tolerated dose (MTD), dose limiting&#xD;
      toxicity (DLT), safety and pharmacokinetics (PK) profile of a single agent CKD-516 injection&#xD;
      on a weekly schedule in patients with advanced solid cancers failed to standard therapy. The&#xD;
      usefulness of the this regimen is evaluated by response rate, progression free survival and&#xD;
      vascular disruption effect by Dynamic Contrast-Enhanced MRI (DCE-MRI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  I. Determine the maximum tolerated dose of CKD-516 administered at single doses every 21&#xD;
           days in patients with advanced solid tumors.&#xD;
&#xD;
        -  II. Determine both the toxicity and dose limiting toxicity of this regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  III. Determine the plasma and urine pharmacokinetics of CKD-516.&#xD;
&#xD;
        -  IV. Gather preliminary data regarding possible antitumor effects in those patients with&#xD;
           measurable diseae. Assess the effects of CKD-516 on tumor blood flow using DCE-MRI&#xD;
           scanning techniques, and establish the dose at which these effects occur.&#xD;
&#xD;
      OUTLINE: This is an open label, dose escalation study. Patients receive CKD-516 IV over 30&#xD;
      minutes on day 1, 8 every 3 weeks in the absence of unacceptable toxicity or disease&#xD;
      progression. Cohorts of 3~6 patients receive escalating doses of CKD-516 until the maximum&#xD;
      tolerated dose(MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose limiting toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD, Maximum Tolerated Dose</measure>
    <time_frame>1st cycle</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of CKD-516 and its metabolite, S516, when CKD-516 administered on Days 1 and 8 of a 21-day cycle</measure>
    <time_frame>1st cycle</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting Toxicity</measure>
    <time_frame>1st cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR%, Objective response rate</measure>
    <time_frame>every 2 cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS, Progression Free Survival</measure>
    <time_frame>30 days before or after last patient out</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular disruption effect(with DCE-MRI)</measure>
    <time_frame>24hr after 1st cycle day 1 treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>CKD-516 inj</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-516 inj</intervention_name>
    <description>5.0 mg/2ml; 1.0, 2.0, 3.3, 5, 7, 9 ~ mg/m2; Day 1, Day 8 every 3 weeks</description>
    <arm_group_label>CKD-516 inj</arm_group_label>
    <other_name>CKD-516</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  20~75 years&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid tumors that have failed to standard&#xD;
             therapy or for which no life prolonging treatment exists&#xD;
&#xD;
          -  ECOG PS 0-2&#xD;
&#xD;
          -  Life expectancy 12 weeks&#xD;
&#xD;
          -  Hematopoietic: ANC ≥ 1,500/mm3, Platelet ≥ 100,000/mm3, Hemoglobin ≥ 9.0g/dL,&#xD;
             Prothrombin time, Activated partial thromboplastin time: normal range&#xD;
&#xD;
          -  Hepatic: total bilirubin ≤ 1.5×ULN(except Gilbert's syndrome patients), AST, ALT ≤&#xD;
             3.0×ULN(AST, ALT ≤ 5.0×ULN in case of liver metastases)&#xD;
&#xD;
          -  Renal: serum creatinine ≤ 1.5×ULN or Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Signed a written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Brain or Leptomeningeal metastases&#xD;
&#xD;
          -  History of Ischemic heart disease(e.g., myocardial infarction, unstable angina&#xD;
             pectoris) or Clinically significant heart disease such as NYHA Class III and IV&#xD;
             Congestive atrial arrhythmias, within 6 months prior to first dose of study drug&#xD;
&#xD;
          -  Stable angina pectoris shown symptoms within 6 months prior to first dose of study&#xD;
             durg, or Clinically significant abnormality on EKG or echocardiogram(e.g., LVEF &lt; 50%&#xD;
             or clinically significant heart wall abnormality or heart muscle damage)&#xD;
&#xD;
          -  Cerebrovascular disease such as stroke&#xD;
&#xD;
          -  Grade 2 or greater motor or sensory peripheral neuropathy&#xD;
&#xD;
          -  Clinically significant eye diseases(e.g., Glaucoma or Proliferative diabetic&#xD;
             retinopathy, Atrophic macular degeneration), or other clinically significant&#xD;
             abnormality on screening visit&#xD;
&#xD;
          -  Uncontrolled hypertension(greater than 150 mmHg systolic anc 100 mmHg diastolic&#xD;
             regardless of medication)&#xD;
&#xD;
          -  acute infection or blooding tendencies that would preclude study compliance&#xD;
&#xD;
          -  Serious vascular disease such as Aortic aneurysm&#xD;
&#xD;
          -  Other psychiatric disorders or other conditions that would preclude study compliance&#xD;
&#xD;
          -  Receiving anticoagulation with warfarin, heparin, etc.&#xD;
&#xD;
          -  Receiving antitumor therapy(surgery, immunotherapy or chemotherapy) within 4 weeks&#xD;
             prior to first dose of study drug(6 weeks for nitrosoureas and mitomycin C, 2 weeks&#xD;
             for radiation therapy)&#xD;
&#xD;
          -  Other concurrent antitumor therapy&#xD;
&#xD;
          -  History of Serious hypersensitivity or allergy&#xD;
&#xD;
          -  Pregnant or nursing, active serum pregnancy test. Fertile patients must use effective&#xD;
             contraception&#xD;
&#xD;
          -  Participation in a clinical trial within 4 weeks of first dose of study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yung-Jue Bang, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>December 3, 2009</study_first_submitted>
  <study_first_submitted_qc>December 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <last_update_submitted>December 20, 2011</last_update_submitted>
  <last_update_submitted_qc>December 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chong Kun Dang Pharmaceutical</name_title>
    <organization>Medical Department</organization>
  </responsible_party>
  <keyword>Tubulin polymerization inhibitor</keyword>
  <keyword>CKD-516</keyword>
  <keyword>Phase I</keyword>
  <keyword>Vascular disrupting agent</keyword>
  <keyword>DCE MRI</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

